An analysis of a randomized trial of 203 veterans with PTSD found that Transcendental Meditation (TM) was more cost-effective than Prolonged Exposure (PE) therapy or health education (HE). TM cost $1,504 for 12 sessions, while PE cost $2,822 and HE cost $492. TM was non-inferior to PE for improving PTSD symptoms, and both TM and PE outperformed HE. Clinically significant improvement occurred in 61% of the TM group, 42% of the PE group, and 32% of the HE group. Higher healthcare costs for non-responders offset the lower intervention cost of HE, making TM the dominant strategy over both alternatives over a 5-year horizon.
Transcendental Meditation (TM) is at least as effective as prolonged exposure therapy (PE) for reducing PTSD symptoms in military veterans, and both therapies outperform PTSD health education alone. In a randomized trial of 203 veterans with PTSD from active service, TM was non-inferior to PE on the primary outcome of symptom severity change over three months. Both TM and PE produced significantly greater reductions in PTSD symptoms than health education. 61% of veterans receiving TM showed clinically significant improvement, compared with 42% receiving PE and 32% receiving health education. TM may offer an effective alternative for veterans who prefer not to undergo trauma-focused treatment.
Incarcerated men with moderate- to high-risk criminal profiles who practiced Transcendental Meditation for four months showed significant reductions in trauma symptoms—including anxiety, depression, dissociation, and sleep disturbance—as well as perceived stress, compared with those receiving usual care. The benefits were especially pronounced among those with high trauma levels, with effect sizes ranging from 0.67 to 0.89. These findings align with earlier research on Transcendental Meditation's effects on trauma and stress.
A randomized controlled trial is underway comparing Transcendental Meditation (TM) to Prolonged Exposure (PE) therapy and a health education control for posttraumatic stress disorder in 210 Veterans meeting DSM-IV criteria. The study will measure PTSD symptoms, depression, mood, quality of life, behavioral factors, and physiological/biochemical and gene expression mechanisms at 0 and 3 months. The hypothesis is that TM will be noninferior to PE and superior to the control on changes in PTSD symptoms as assessed by the Clinician Administered PTSD Scale. This protocol aims to establish TM's efficacy for PTSD in Veterans and identify underlying mechanisms.